Dr. Richard Lin is the Founder and CEO of Explora BioLabs, a San Diego based preclinical pharmacology contract research company. With over 20 years of academic research and biotech drug development experience, Richard brought his substantial scientific background to the research service industry. Prior to founding Explora BioLabs, Richard served as a Research Investigator at Ansata Therapeutics. He headed the group responsible for the preclinical development of Ansata’s novel antimicrobial peptides in support of their advancement toward IND filing. Richard also served as head of the Physiology Department at Genset Corporation, where he led the effort to determine the in vivo functions of Genset’s leading therapeutic proteins in the areas of obesity and diabetes. Richard’s earlier biotech experience included a Group Leader position at Corvas International, and a Senior Scientist position at Axys Pharmaceuticals. Richard conducted his postdoctoral research at UC San Diego Cancer Center, and received his PhD in Zoology from UC Berkeley.
Explora BioLabs is a San Diego based preclinical pharmacology contract research company that provides custom-tailored discovery pharmacology services focusing on PK, non-GLP toxicology, oncology, infectious and metabolic diseases, wound healing and novel model development. The company delivers professionally-managed, cost-effective, premium vivarium services, enabling pharma, biotech and leading academic researchers to accelerate their preclinical programs by virtualizing their pharmacology infrastructure.